AbbVie Inc at UBS Global Healthcare Conference Transcript

May 21, 2019 / 12:30PM GMT
Navin Cyriac Jacob - UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic

Good morning. Welcome to day 2 of the UBS Healthcare Conference. My name is Navin Jacob. I'm the senior analyst covering large-cap pharmaceuticals and SMID cap biotech.

I'm happy to have here with me today the management -- some of the management team from AbbVie. Today, we have Mike Severino, Vice Chairman and President as well as Robert Michael, SVP and CFO. Thanks for having us, guys.

Robert A. Michael - AbbVie Inc. - Senior VP & CFO

Pleasure to be here.

Questions and Answers:

Navin Cyriac Jacob - UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic

So maybe we could start with a topic that is always in the front of investors' minds, HUMIRA ex U.S. and the erosion that we're seeing there. On the Q1 call, you guided to Q2 HUMIRA OUS revenues of $1 billion internationally. That's about 33%
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot